Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling

D A Frank1, S Mahajan, J Ritz

  • 1Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA. david_frank@dfci.harvard.edu

Nature Medicine
|April 15, 1999
PubMed

Insights

Fludarabine, a cancer drug, suppresses the immune system by reducing STAT1 protein levels in lymphocytes. This STAT1 depletion explains the drug's immunosuppressive effects and suggests STAT1 as a target for new therapies.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Fludarabine is a nucleoside analog used for hematologic malignancies, causing significant immunosuppression.
  • Its mechanism involves DNA incorporation but also affects non-dividing cells, suggesting other actions.
  • Signal transducer and activator of transcription 1 (STAT1) is crucial for cell-mediated immunity and viral defense.

Purpose of the Study:

  • To investigate the mechanism of fludarabine-induced immunosuppression.
  • To determine if fludarabine affects STAT1 activation and expression.
  • To explore STAT1 as a potential therapeutic target.

Main Methods:

  • Comparing fludarabine and cyclosporine A effects on cytokine-induced STAT1 activation in lymphocytes.
  • Assessing STAT1 protein and mRNA levels after fludarabine treatment.
  • Analyzing STAT1 levels in patients treated with fludarabine.

Main Results:

  • Fludarabine specifically inhibited STAT1 activation and STAT1-dependent gene transcription in lymphocytes.
  • Fludarabine treatment led to a significant depletion of STAT1 protein and mRNA.
  • STAT1 loss was observed in patients receiving fludarabine, correlating with prolonged immunosuppression.

Conclusions:

  • Fludarabine induces immunosuppression by depleting STAT1 in lymphocytes.
  • STAT1 is a key mediator of fludarabine's immunosuppressive effects.
  • Targeting STAT1 may lead to novel immunosuppressive and antineoplastic agents.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...